Core Viewpoint - TaiLi Bio is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies, with its core candidate drug TSN1611 being a selective oral KRAS G12D inhibitor [1][3]. Group 1: Company Overview - TaiLi Bio was established in 2017 and has submitted its listing application to the Hong Kong Stock Exchange [1]. - The company has a pipeline that includes four candidate drugs, with TSN1611 currently in Phase 2 clinical trials in the US and China [3]. Group 2: Financial Performance - The company reported net losses of 70.461 million yuan and 123 million yuan for the first three quarters of 2024 and 2025, respectively [1][6]. - Research and development expenses for the same periods were 72.813 million yuan and 91.17 million yuan [6]. Group 3: Business Model and Strategy - TaiLi Bio's business model focuses on the independent discovery and development of innovative drugs in the oncology field, particularly small molecule drugs and ADC candidates [3]. - The company aims to accelerate the clinical development and commercialization of TSN1611 and plans to pursue external collaborations to maximize the global value of its technology platform and product pipeline [3][4]. Group 4: Research and Development - The company has established three core self-developed technology platforms that provide a competitive advantage in the development of small molecules and ADCs [3]. - As of January 23, 2026, TaiLi Bio holds 97 patents and patent applications [6]. Group 5: Regulatory Status - As of the latest update, TaiLi Bio has not received any regulatory approvals for its candidate drugs and has not generated any revenue from product sales [6].

Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [3][4]. Financial Information - The company reported revenues of RMB 7.856 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 11.358 million for the nine months ending September 30, 2025 [7]. - The company incurred losses of approximately RMB 70.461 million for the fiscal year 2024, RMB 28.354 million for the nine months ending September 30, 2024, and RMB 123.406 million for the nine months ending September 30, 2025 [8]. - Gross profits were reported as RMB 7.121 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 8.894 million for the nine months ending September 30, 2025 [9]. Industry Overview - Cancer is a leading cause of death globally, with approximately 10 million deaths annually. In 2024, there are expected to be 21.3 million new cancer cases, projected to rise to 27.1 million by 2035. In China, the most prevalent cancers are lung, colorectal, and thyroid cancers [10]. - The global oncology drug market has expanded significantly, with a market size growing from USD 150.3 billion in 2020 to USD 253.3 billion in 2024, reflecting a compound annual growth rate (CAGR) of 13.9%. It is expected to reach USD 702.7 billion by 2035, with immunotherapy being a major growth driver [10]. - The Chinese oncology drug market has also seen rapid growth, increasing from RMB 197.5 billion in 2020 to RMB 258.2 billion in 2024, with a CAGR of 6.9%. It is projected to reach RMB 1.04 trillion by 2035, with immuno-oncology drugs' market share expected to surge from 7.5% in 2020 to 47.5% by 2035 [13].

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a highly selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets KRAS G12D, one of the most common oncogenic driver mutations, which has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials for non-small cell lung cancer (NSCLC) in China [1] - Additional candidates in the pipeline include TSN222, a Phase 2 clinical candidate, and two preclinical candidates, TSNA1789 and TSNA3399 [1]

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets the KRAS G12D mutation, which is one of the most common oncogenic driver mutations and has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials in China for the treatment of non-small cell lung cancer (NSCLC) [1]

Core Viewpoint - The stock price of 加科思-B (01167) increased by 6.17% to HKD 8.09, with a trading volume of HKD 17.6587 million, following the announcement of a capital increase and equity transfer agreement [1][5] Group 1: Financial Developments - 加科思's subsidiary, 北京加科思, received a first payment of RMB 125 million from 海松资本 as part of the capital increase and equity transfer agreement, enhancing the group's cash reserves [1][5] - The influx of funds is expected to support the development of innovative cancer therapy pipelines [1][5] Group 2: Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, were published in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1][5] - This publication marks the first systematic clinical data on the combination of KRAS G12C and SHP2 dual oral small molecule therapy to be featured in such a high-profile journal [1][5]

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, with a current price of HKD 8.04 and a trading volume of HKD 8.1525 million. The company has received a substantial payment that enhances its cash reserves and supports its ongoing research in innovative cancer therapies [1]. Group 1 - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, which bolsters the group's cash reserves [1]. - The receipt of this payment is expected to facilitate the advancement of the company's pipeline for innovative cancer therapies [1]. Group 2 - Gossamer Bio announced the publication of clinical I/IIa study results for its self-developed KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312 (Sitneprotafib) in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1]. - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has been featured in such a reputable journal [1].

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, attributed to positive developments in the company's financial and clinical research activities [1] Financial Developments - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the company's innovative oncology therapy pipeline [1] Clinical Research Achievements - Gossamer Bio announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, Glecirasib, in combination with the SHP2 inhibitor, JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]

Core Viewpoint - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for patients with limited treatment options, and is currently advancing its lead candidate APL-101 (vebreltinib) through global clinical trials [1][3]. Group 1: Company Overview - Apollomics has 9 drug candidates in its pipeline, with 6 in clinical development targeting challenging cancers such as lung cancer and brain cancer [1]. - The company employs a strategy that combines targeted therapies, immuno-oncology, and innovative mechanisms of action to overcome resistance and achieve clinically meaningful efficacy [1]. Group 2: Recent Developments - On August 28, 2025, Apollomics announced plans to terminate all clinical trial activities related to APL-101 due to financial issues and sought shareholder approval for liquidation [2]. - Following a PIPE investment of $4.1 million on September 3, 2025, the company appointed a new board and management team, including Howard Chen as CEO and Alex Chen as COO [2]. Group 3: Clinical Trials and Future Plans - After securing additional funding and a new management team, Apollomics canceled its liquidation plans and will continue its existing operations, including the global development of APL-101 [3]. - The company is committed to completing the SPARTA clinical trials for APL-101, which are crucial for maximizing its therapeutic potential across various tumor types and supporting regulatory submissions in major markets [4]. - Apollomics plans to leverage its partnerships in China to advance regulatory submissions for APL-101 in emerging markets outside of Southeast Asia and the Middle East [4]. Group 4: Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase the workforce to 15 by October 31, 2025, while also reducing staff in mainland China and reallocating resources to the U.S. and Taiwan [4].